UK Markets closed
  • NIKKEI 225

    26,571.87
    +140.32 (+0.53%)
     
  • HANG SENG

    17,860.31
    +5.17 (+0.03%)
     
  • CRUDE OIL

    78.24
    -0.26 (-0.33%)
     
  • GOLD FUTURES

    1,636.40
    +0.20 (+0.01%)
     
  • DOW

    29,134.99
    -125.82 (-0.43%)
     
  • BTC-GBP

    17,785.51
    -158.70 (-0.88%)
     
  • CMC Crypto 200

    436.57
    -22.57 (-4.92%)
     
  • Nasdaq

    10,829.50
    +26.58 (+0.25%)
     
  • ^FTAS

    3,810.44
    -31.01 (-0.81%)
     

We're Not Very Worried About e-therapeutics' (LON:ETX) Cash Burn Rate

·4-min read

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Given this risk, we thought we'd take a look at whether e-therapeutics (LON:ETX) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

View our latest analysis for e-therapeutics

How Long Is e-therapeutics' Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at July 2021, e-therapeutics had cash of UK£32m and no debt. In the last year, its cash burn was UK£4.6m. That means it had a cash runway of about 6.9 years as of July 2021. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is e-therapeutics' Cash Burn Changing Over Time?

In the last year, e-therapeutics did book revenue of UK£757k, but its revenue from operations was less, at just UK£757k. We don't think that's enough operating revenue for us to understand too much from revenue growth rates, since the company is growing off a low base. So we'll focus on the cash burn, today. Over the last year its cash burn actually increased by 39%, which suggests that management are increasing investment in future growth, but not too quickly. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. In reality, this article only makes a short study of the company's growth data. You can take a look at how e-therapeutics is growing revenue over time by checking this visualization of past revenue growth.

Can e-therapeutics Raise More Cash Easily?

Given its cash burn trajectory, e-therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of UK£133m, e-therapeutics' UK£4.6m in cash burn equates to about 3.5% of its market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

How Risky Is e-therapeutics' Cash Burn Situation?

It may already be apparent to you that we're relatively comfortable with the way e-therapeutics is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 3 warning signs for e-therapeutics that potential shareholders should take into account before putting money into a stock.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.